Use of &agr;1C specific compounds to treat benign prostatic hyperplasia

US6602888B2 · kind B2 · utility

Assignee

• Synaptic Pharmaceutical Corporation · US

Inventors

• Charles Gluchowski · Mission Viejo, US
• Carlos Forray · Paramus, US
• George Chiu · Bound Brook, US
• Theresa Branchek · Teaneck, US
• John Wetzel · Elmwood Park, US
• Paul R. Hartig · Mahwah, US

Key dates

• Filing date: Nov 22, 1999
• Grant date: Aug 5, 2003
• Expiry date: Nov 22, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07C2602/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor, and, binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor. Compounds meeting these criteria are provided.